Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption
Introduction Bile acid malabsorption (BAM) is a socially debilitating disease characterised by high stool frequency and urgency caused by a spillover of bile acids into the colon. Bile acid sequestrants (BASs) have limited therapeutic effect but represent the only available treatment option. Cases r...
Main Authors: | Filip K Krag Knop, Martin Lund Kårhus, Andreas Brønden, Julie Lyng Forman, Anne Haaber, David Peick Sonne |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/11/2/e044711.full |
Similar Items
-
Mechanisms of idiopathic bile acid malabsorption and diarrhoea
by: Pattni, Sanjeev
Published: (2013) -
Bile Acid Malabsorption in Chronic Diarrhea: Pathophysiology and Treatment
by: Alan Barkun, et al.
Published: (2013-01-01) -
Methods for diagnosing bile acid malabsorption: a systematic review
by: Ivan Lyutakov, et al.
Published: (2019-11-01) -
FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption
by: Diana Jung, et al.
Published: (2007-12-01) -
SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis
by: R Riemsma, et al.
Published: (2013-12-01)